Taiwan Advance Bio-Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$233.9M and total debt of NT$299.7M, which brings its debt-to-equity ratio to 128.1%. Its total assets and total liabilities are NT$748.6M and NT$514.7M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$2.4M making its interest coverage ratio 0.4. It has cash and short-term investments of NT$182.1M.
Key information
128.1%
Debt to equity ratio
NT$299.69m
Debt
| Interest coverage ratio | 0.4x |
| Cash | NT$182.14m |
| Equity | NT$233.92m |
| Total liabilities | NT$514.65m |
| Total assets | NT$748.57m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4186's short term assets (NT$259.3M) do not cover its short term liabilities (NT$316.8M).
Long Term Liabilities: 4186's short term assets (NT$259.3M) exceed its long term liabilities (NT$197.8M).
Debt to Equity History and Analysis
Debt Level: 4186's net debt to equity ratio (50.3%) is considered high.
Reducing Debt: 4186's debt to equity ratio has increased from 125.9% to 128.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 4186 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 4186 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.5% per year.